OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+1.9%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$681M
AUM Growth
+$681M
(-11%)
Cap. Flow
-$30.5M
Cap. Flow
% of AUM
-4.47%
Top 10 Holdings %
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$36M |
| 2 |
AUTL
Autolus Therapeutics
AUTL
|
$12.1M |
| 3 |
Disc Medicine
IRON
|
$11M |
| 4 |
Keros Therapeutics
KROS
|
$9.69M |
| 5 |
MacroGenics
MGNX
|
$9.41M |
Top Sells
| 1 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$41.5M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$21.7M |
| 3 |
TG Therapeutics
TGTX
|
$20.2M |
| 4 |
Cardiff Oncology
CRDF
|
$10.1M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$8.93M |
Sector Composition
| 1 | Healthcare | 98.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Avalo Therapeutics
AVTX
$122M
| $7.85M | 1.15% | 2,600,000 -20,000 | -0.8% | -$60.4K |
|
27
Sutro Biopharma
STRO
$72.7M
| $7.78M | 1.14% | 341,950 +19,750 | +6% | +$450K |
|
28
Protagonist Therapeutics
PTGX
$3.67B
| $7.69M | 1.13% | 297,000 +37,000 | +14% | +$958K |
|
29
Immunovant
IMVT
$2.56B
| $7.49M | 1.1% | +467,000 | New | +$7.49M |
|
30
Vaxcyte
PCVX
$4B
| $7.07M | 1.04% | 357,800 +22,600 | +7% | +$446K |
|
31
Sanara MedTech
SMTI
$300M
| $7.01M | 1.03% | +225,000 | New | +$7.01M |
|
32
Gyre Therapeutics
GYRE
$703M
| $6.3M | 0.93% | 1,250,000 +1,101,200 | +740% | +$5.55M |
|
|
AVEO
33
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $6.11M | 0.9% | 835,000 +776,200 | +1,320% | +$5.68M |
|
34
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $5.94M | 0.87% | 320,926 +96,826 | +43% | +$1.79M |
|
35
Verastem
VSTM
$569M
| $5.74M | 0.84% | 2,325,000 | – | – |
|
36
TELA Bio
TELA
$70.5M
| $5.44M | 0.8% | 365,000 | – | – |
|
37
MEI Pharma
MEIP
$160M
| $5.34M | 0.78% | 1,556,000 | – | – |
|
|
38
Cardiff Oncology
CRDF
$140M
| $5.33M | 0.78% | 576,000 -1,086,500 | -65% | -$10.1M |
|
|
SIOX
39
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $5.22M | 0.77% | 2,000,000 | – | – |
|
|
APTO
40
DELISTED
Aptose Biosciences, Inc.
APTO
| $5.21M | 0.77% | 871,800 +71,800 | +9% | +$429K |
|
|
MYOV
41
DELISTED
Myovant Sciences Ltd.
MYOV
| $5.14M | 0.76% | 249,800 -432,700 | -63% | -$8.91M |
|
42
FibroGen
FGEN
$47.8M
| $5.1M | 0.75% | 147,000 | – | – |
|
|
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $4.41M | 0.65% | 376,900 +95,613 | +34% | +$1.12M |
|
44
Kezar Life Sciences
KZR
$28.9M
| $4.24M | 0.62% | 711,200 +3,200 | +0.5% | +$19.1K |
|
|
OPTN
45
DELISTED
OptiNose
OPTN
| $3.05M | 0.45% | 826,000 +391,000 | +90% | +$1.44M |
|
46
Quantum-Si Incorporated
QSI
$227M
| $2.88M | 0.42% | +241,300 | New | +$2.88M |
|
47
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.87M | 0.42% | +188,000 | New | +$2.87M |
|
|
EDAP
48
EDAP TMS
EDAP
$84.5M
| $2.87M | 0.42% | 341,300 -316,200 | -48% | -$2.66M |
|
|
SRRA
49
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.6M | 0.38% | 151,139 +75,760 | +101% | +$1.31M |
|
|
BHVN
50
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $1.71M | 0.25% | 25,000 -89,000 | -78% | -$6.08M |
|